XML 112 R94.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Schedule of Segment Reporting Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Revenues $ 105,757 $ 113,450
Cost of revenues 3,884 4,636
Gross profit 101,873 108,814
Operating expenses excluding cost of revenues:    
Selling and marketing 57,511 61,159
Research and development 12,024 13,780
General and administrative 16,109 14,662
Acquired in-process research and development   83,104
Divestiture losses   2,711
Loss on disposal of property and equipment 66 628
Total operating expenses excluding cost of revenues 85,710 176,044
Income (Loss) from operations 16,163 (67,230)
Interest income, net 1,547 1,044
Other expense, net (1,659) (1,518)
Change in fair value of warrant liability 7,167 (9,261)
Income tax expense (5,320) (8,515)
Net income (loss) 17,898 (85,480)
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation 831 7,281
Total assets 125,406 116,539
Purchase of property and equipment (2,315) (8,517)
Cost of revenue    
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation   52
Selling and Marketing    
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation   344
Research and Development    
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation   481
General and administrative    
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation 831 6,404
Gyre Pharmaceuticals    
Segment Reporting Information [Line Items]    
Revenues 105,757 113,450
Cost of revenues 3,884 4,636
Gross profit 101,873 108,814
Operating expenses excluding cost of revenues:    
Selling and marketing 57,511 61,159
Research and development 11,224 13,698
General and administrative 11,051 8,872
Loss on disposal of property and equipment 66 628
Total operating expenses excluding cost of revenues 79,852 84,357
Income (Loss) from operations 22,021 24,457
Interest income, net 1,321 1,044
Other expense, net (1,329) (1,246)
Income tax expense (5,318) (8,509)
Net income (loss) 16,695 15,746
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation   2,793
Total assets 114,248 101,761
Purchase of property and equipment (2,301) (8,517)
Gyre Pharmaceuticals | Cost of revenue    
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation   52
Gyre Pharmaceuticals | Selling and Marketing    
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation   344
Gyre Pharmaceuticals | Research and Development    
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation   481
Gyre Pharmaceuticals | General and administrative    
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation   1,916
Gyre    
Operating expenses excluding cost of revenues:    
Research and development 800 82
General and administrative 5,056 5,214
Acquired in-process research and development   83,104
Total operating expenses excluding cost of revenues 5,856 88,400
Income (Loss) from operations (5,856) (88,400)
Interest income, net 232  
Other expense, net (336) (272)
Change in fair value of warrant liability 7,167 (9,261)
Income tax expense (2) (6)
Net income (loss) 1,205 (97,939)
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation 831 4,488
Total assets 10,790 13,865
Purchase of property and equipment (14)  
Gyre | General and administrative    
Supplemental Disclosure of stock-based compensation expense    
Stock-based compensation 831 4,488
Other    
Operating expenses excluding cost of revenues:    
General and administrative 2 576
Divestiture losses   2,711
Total operating expenses excluding cost of revenues 2 3,287
Income (Loss) from operations (2) (3,287)
Interest income, net (6)  
Other expense, net 6  
Net income (loss) (2) (3,287)
Supplemental Disclosure of stock-based compensation expense    
Total assets $ 368 $ 913